Embracing the Digital Revolution: How Artificial Intelligence is Transforming Clinical Trials in Older Participants.

IF 4.2 3区医学 Q2 GERIATRICS & GERONTOLOGY

Drugs & Aging Pub Date : 2026-03-01 Epub Date: 2026-03-04 DOI:10.1007/s40266-026-01288-8

Yaru Wang, Miao Miao, Qingqing Wang, Yuyin Yin, Haijuan Zhao, Shuang Zhao, Han Yang, Xin Wang

{"title":"Embracing the Digital Revolution: How Artificial Intelligence is Transforming Clinical Trials in Older Participants.","authors":"Yaru Wang, Miao Miao, Qingqing Wang, Yuyin Yin, Haijuan Zhao, Shuang Zhao, Han Yang, Xin Wang","doi":"10.1007/s40266-026-01288-8","DOIUrl":null,"url":null,"abstract":"<p><p>Artificial intelligence (AI) is revolutionizing clinical trials in geriatric populations by addressing the unique challenges of aging-related diseases and patient heterogeneity. Advanced AI techniques, including machine learning, deep learning, and AI-driven digital health platforms, enable intelligent patient stratification, risk prediction, and real-time monitoring tailored to older adults. AI facilitates the design and execution of decentralized clinical trials, improving accessibility and compliance among older participants. Moreover, AI-powered digital twins and predictive models enhance safety assessments and treatment personalization, optimizing therapeutic outcomes. By integrating multi-omics data, electronic health records, and wearable device outputs, AI enables precise and dynamic decision-making throughout the trial lifecycle. This approach not only increases trial efficiency and accuracy but also supports ethical, patient-centered research practices. This review explores the transformative role of AI in geriatric clinical trials, outlining key advancements, practical challenges, and strategic directions for establishing AI as a catalyst for precision medicine in aging populations.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"239-250"},"PeriodicalIF":4.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-026-01288-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Artificial intelligence (AI) is revolutionizing clinical trials in geriatric populations by addressing the unique challenges of aging-related diseases and patient heterogeneity. Advanced AI techniques, including machine learning, deep learning, and AI-driven digital health platforms, enable intelligent patient stratification, risk prediction, and real-time monitoring tailored to older adults. AI facilitates the design and execution of decentralized clinical trials, improving accessibility and compliance among older participants. Moreover, AI-powered digital twins and predictive models enhance safety assessments and treatment personalization, optimizing therapeutic outcomes. By integrating multi-omics data, electronic health records, and wearable device outputs, AI enables precise and dynamic decision-making throughout the trial lifecycle. This approach not only increases trial efficiency and accuracy but also supports ethical, patient-centered research practices. This review explores the transformative role of AI in geriatric clinical trials, outlining key advancements, practical challenges, and strategic directions for establishing AI as a catalyst for precision medicine in aging populations.

查看原文本刊更多论文

拥抱数字革命：人工智能如何改变老年参与者的临床试验。

人工智能（AI）通过解决与衰老相关的疾病和患者异质性的独特挑战，正在彻底改变老年人群的临床试验。先进的人工智能技术，包括机器学习、深度学习和人工智能驱动的数字健康平台，可实现针对老年人的智能患者分层、风险预测和实时监测。人工智能促进了分散临床试验的设计和执行，提高了老年参与者的可及性和依从性。此外，人工智能驱动的数字双胞胎和预测模型增强了安全性评估和治疗个性化，优化了治疗结果。通过集成多组学数据、电子健康记录和可穿戴设备输出，人工智能可以在整个试验生命周期中实现精确和动态的决策。这种方法不仅提高了试验效率和准确性，而且支持道德的、以患者为中心的研究实践。本文探讨了人工智能在老年临床试验中的变革性作用，概述了将人工智能作为老龄化人口精准医疗催化剂的关键进展、实际挑战和战略方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs & Aging 医学-老年医学

CiteScore

5.50

自引率

7.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.